Clinical Trial: UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis

U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06933563) titled 'UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis' on April 02.

Brief Summary: This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Myasthenia gravis. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Myasthenia Gravis

Intervention: BIOLOGICAL: UCAR T-cell group

A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Zhejiang...